Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Noah Lee

Family Medicine Oakland Park, FL Doctor of Osteopathy

NPI 1275559106 CMS profile 239001

1421 E Oakland Park Blvd, Suite 101, Oakland Park, FL 33334

Open in the dashboard

General payments

$1,164,533

2,663 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$125,704 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Noah Lee of Oakland Park, FL is reported in the CMS Open Payments database as having received $1,164,533 across 2,663 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $125,704 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $189,344 372
2024 General $247,175 327
2023 General $177,011 367
2022 General $170,635 346
2021 General $94,346 383
2020 General $66,653 326
2019 General $219,369 542

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Noah Lee
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Noah Lee were reported at $189,344. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Noah Lee Family Medicine median Middle half National median
2019 $219,369 $150 $41–$543 $163
2020 $66,653 $120 $32–$415 $114
2021 $94,346 $137 $35–$551 $132
2022 $170,635 $137 $37–$512 $149
2023 $177,011 $149 $42–$545 $160
2024 $247,175 $156 $44–$560 $164
2025 $189,344 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ViiV Healthcare Company $490,183 607 payments
  2. Gilead Sciences, Inc. $305,095 650 payments
  3. Janssen Products, LP $88,982 76 payments
  4. EMD Serono, Inc. $69,340 92 payments
  5. AbbVie, Inc. $56,355 139 payments
  6. Theratechnologies Inc. $38,229 81 payments
  7. Janssen Pharmaceuticals, Inc $34,121 94 payments
  8. Napo Pharmaceuticals Inc $32,361 68 payments
  9. Merck Sharp & Dohme Corporation $23,183 98 payments
  10. Amgen Inc. $13,557 77 payments
  11. Other $13,126 681 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $907,365 386 payments
  2. Travel and Lodging $111,933 205 payments
  3. Food and Beverage $60,468 2,022 payments
  4. Honoraria $39,735 26 payments
  5. Consulting Fee $37,356 17 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $7,631 2 payments
  7. Education $44 5 payments
Products named General payments · program years 2019–2025
  1. DOVATO $180,026 237 payments
  2. Descovy $146,334 140 payments
  3. APRETUDE $135,105 109 payments
  4. SYMTUZA $89,555 112 payments
  5. Biktarvy $69,508 79 payments
  6. Serostim $63,060 49 payments
  7. MAVYRET $55,613 96 payments
  8. CABENUVA $48,241 70 payments
  9. RUKOBIA $46,727 65 payments
  10. Yeztugo $39,736 34 payments
  11. Other $234,734 1,603 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 271 drugs

Part D claims

18,389

Median for Family Practice: 1,826

Drug cost

$15,703,958

Median for Family Practice: $120,094

Branded share of claims

35.3%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Serostim Somatropin Brand 115 $3,366,220
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 759 $3,232,262
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 254 $1,354,219
Descovy Emtricitabine/Tenofov Alafenam Brand 445 $1,014,216
Rukobia Fostemsavir Tromethamine Brand 71 $647,461
Egrifta Sv Tesamorelin Acetate Brand 73 $631,092
Tivicay Dolutegravir Sodium Brand 229 $598,898
Dovato Dolutegravir Sodium/Lamivudine Brand 172 $515,592
Prezcobix Darunavir/Cobicistat Brand 158 $406,923
Pifeltro Doravirine Brand 199 $399,802

The 10 drugs with the highest cost, of 271 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$227,459

Of which drugs: $15,814

Medicare patients

312

Average age 70

Services billed

5,682

26 women, 286 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 40%
Depression 37%
Ischemic heart disease 34%
Diabetes 30%
Chronic kidney disease 26%
COPD 18%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 13 13 $3,751
Vaccine for influenza for injection into muscle 90662 Office 15 15 $1,227

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 43 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
APRETUDE
$62,405 — —
Descovy
$57,482 445 —
DOVATO
$44,023 172 —
RUKOBIA
$23,452 71 —
CABENUVA
$22,556 44 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 43 with Patron

Records

2,663 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record